239 related articles for article (PubMed ID: 32975292)
1. Effects of Psychotropics on the Microbiome in Patients With Depression and Anxiety: Considerations in a Naturalistic Clinical Setting.
Tomizawa Y; Kurokawa S; Ishii D; Miyaho K; Ishii C; Sanada K; Fukuda S; Mimura M; Kishimoto T
Int J Neuropsychopharmacol; 2021 Feb; 24(2):97-107. PubMed ID: 32975292
[TBL] [Abstract][Full Text] [Related]
2. Psychotropics and the Microbiome: a Chamber of Secrets….
Cussotto S; Clarke G; Dinan TG; Cryan JF
Psychopharmacology (Berl); 2019 May; 236(5):1411-1432. PubMed ID: 30806744
[TBL] [Abstract][Full Text] [Related]
3. The Microbiota-Gut-Brain Axis in Mental Health and Medication Response: Parsing Directionality and Causality.
Bastiaanssen TFS; Cryan JF
Int J Neuropsychopharmacol; 2021 Mar; 24(3):216-220. PubMed ID: 33693884
[TBL] [Abstract][Full Text] [Related]
4. Psychobiome Feeding Mind: Polyphenolics in Depression and Anxiety.
Matarazzo I; Toniato E; Robuffo I
Curr Top Med Chem; 2018; 18(24):2108-2115. PubMed ID: 30526463
[TBL] [Abstract][Full Text] [Related]
5. Effects of Atypical Antipsychotic Treatment and Resistant Starch Supplementation on Gut Microbiome Composition in a Cohort of Patients with Bipolar Disorder or Schizophrenia.
Flowers SA; Baxter NT; Ward KM; Kraal AZ; McInnis MG; Schmidt TM; Ellingrod VL
Pharmacotherapy; 2019 Feb; 39(2):161-170. PubMed ID: 30620405
[TBL] [Abstract][Full Text] [Related]
6. Association between fecal microbiota and generalized anxiety disorder: Severity and early treatment response.
Chen YH; Bai J; Wu D; Yu SF; Qiang XL; Bai H; Wang HN; Peng ZW
J Affect Disord; 2019 Dec; 259():56-66. PubMed ID: 31437702
[TBL] [Abstract][Full Text] [Related]
7. Fecal Microbial and Metabolomic Change during treatment course for depression: An Observational Study.
Kurokawa S; Tomizawa Y; Miyaho K; Ishii D; Takamiya A; Ishii C; Sanada K; Fukuda S; Mimura M; Kishimoto T
J Psychiatr Res; 2021 Aug; 140():45-52. PubMed ID: 34091346
[TBL] [Abstract][Full Text] [Related]
8. Where is the room for improvement in the drug treatment of depression and anxiety?
Baldwin DS
Hum Psychopharmacol; 2011 Jan; 26(1):1-3. PubMed ID: 23055413
[No Abstract] [Full Text] [Related]
9. Antidepressants affect gut microbiota and Ruminococcus flavefaciens is able to abolish their effects on depressive-like behavior.
Lukić I; Getselter D; Ziv O; Oron O; Reuveni E; Koren O; Elliott E
Transl Psychiatry; 2019 Apr; 9(1):133. PubMed ID: 30967529
[TBL] [Abstract][Full Text] [Related]
10. Mixed depression and anxiety: serotonin1A receptors as a common pharmacologic link.
Stahl SM
J Clin Psychiatry; 1997; 58 Suppl 8():20-6. PubMed ID: 9236732
[TBL] [Abstract][Full Text] [Related]
11. Assessing the effect of interaction between C-reactive protein and gut microbiome on the risks of anxiety and depression.
Chen Y; Meng P; Cheng S; Jia Y; Wen Y; Yang X; Yao Y; Pan C; Li C; Zhang H; Zhang J; Zhang Z; Zhang F
Mol Brain; 2021 Sep; 14(1):133. PubMed ID: 34481527
[TBL] [Abstract][Full Text] [Related]
12. The role of pharmacogenetics in the treatment of depression and anxiety disorders.
Schosser A; Kasper S
Int Clin Psychopharmacol; 2009 Nov; 24(6):277-88. PubMed ID: 19738481
[TBL] [Abstract][Full Text] [Related]
13. Interaction Between Atypical Antipsychotics and the Gut Microbiome in a Bipolar Disease Cohort.
Flowers SA; Evans SJ; Ward KM; McInnis MG; Ellingrod VL
Pharmacotherapy; 2017 Mar; 37(3):261-267. PubMed ID: 28035686
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal gut microbiome changes in alcohol use disorder are influenced by abstinence and drinking quantity.
Ames NJ; Barb JJ; Schuebel K; Mudra S; Meeks BK; Tuason RTS; Brooks AT; Kazmi N; Yang S; Ratteree K; Diazgranados N; Krumlauf M; Wallen GR; Goldman D
Gut Microbes; 2020 Nov; 11(6):1608-1631. PubMed ID: 32615913
[TBL] [Abstract][Full Text] [Related]
15. Sleep patterns in depression and anxiety: theory and pharmacological effects.
Sandor P; Shapiro CM
J Psychosom Res; 1994; 38 Suppl 1():125-39. PubMed ID: 7799244
[TBL] [Abstract][Full Text] [Related]
16. Concomitant psychotropic medication use during treatment of schizophrenia patients: longitudinal results from the CATIE study.
Chakos M; Patel JK; Rosenheck R; Glick ID; Hammer MB; Tapp A; Miller A; Miller D
Clin Schizophr Relat Psychoses; 2011 Oct; 5(3):124-34. PubMed ID: 21983496
[TBL] [Abstract][Full Text] [Related]
17. Drug development for anxiety disorders: new roles for atypical antipsychotics.
Carson WH; Kitagawa H
Psychopharmacol Bull; 2004; 38(1):38-45. PubMed ID: 15278017
[TBL] [Abstract][Full Text] [Related]
18. Role of Actinobacteria and Coriobacteriia in the antidepressant effects of ketamine in an inflammation model of depression.
Huang N; Hua D; Zhan G; Li S; Zhu B; Jiang R; Yang L; Bi J; Xu H; Hashimoto K; Luo A; Yang C
Pharmacol Biochem Behav; 2019 Jan; 176():93-100. PubMed ID: 30528936
[TBL] [Abstract][Full Text] [Related]
19. Fluoxetine and concomitant centrally acting medication use during clinical trials of depression: the absence of an effect related to agitation and suicidal behavior.
Wernicke JF; Sayler ME; Koke SC; Pearson DK; Tollefson GD
Depress Anxiety; 1997; 6(1):31-9. PubMed ID: 9394873
[TBL] [Abstract][Full Text] [Related]
20. Methamphetamine exposure and its cessation alter gut microbiota and induce depressive-like behavioral effects on rats.
Forouzan S; Hoffman KL; Kosten TA
Psychopharmacology (Berl); 2021 Jan; 238(1):281-292. PubMed ID: 33097978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
